Longevity Executes Merger Agreement With 20/20 Biolabs To Combine Companies In All-stock Transaction; Expects Post-closing Equity Valuation Of Combined Company To Be About $99M

PITTSBURGH, Pa. & GAITHERSBURG, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ:XAGE), a company focused on human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition ("Longevity", the "Company", "we", "our", or "us"), today announced the execution of a merger agreement (the "Merger") with 20/20 BioLabs, Inc. ("20/20"), a leading provider of innovative laboratory tests for the early detection and the proactive management of chronic disease risk, to combine the companies in an all-stock transaction. Following the closing of the Merger (the "Closing"), the combined company is expected to continue to trade on Nasdaq under the symbol "XAGE."

This Merger follows Longevity's acquisition of Elevai Skincare in January 2025. The combination with 20/20 advances the Company's March 10, 2025 announcement of its new strategy to build a footprint in diagnostics to drive synergies with its existing bio-aesthetic portfolio of products and its contemplated expansion into nutrition. Following the Closing, the Company will seek to address the epidemic of chronic disease in America under the banner "Healthy Aging, Inside and Out™", increasingly recognized as an urgent priority by healthcare leaders and policymakers.

Highlights of the 20/20 business are:

• Operates a CLIA Licensed, CAP Accredited lab in Gaithersburg, MD
• Offers OneTestTM, a multi-cancer early detection (MCED) blood test for more than a dozen tumor types including those of the lung, pancreas, ovaries, and liver starting at under $200. A 2024 blinded study by the U.S. National Cancer Institute demonstrated that OneTestTM, likely detects many types of cancers at earlier stages than other leading MCEDs.
• Integrated OneTestTM into routine physical evaluation for thousands of American firefighters and military veterans who may be at a higher risk of cancer.
• The only MCED on the market that uses capillary blood specimens for less painful sample collection.
• A pilot with Giant Food, the largest supermarket chain in the Washington, D.C. area, is expected to be announced this week.
• Expects to launch a "longevity test" Spring 2025 that analyzes several inflammatory biomarkers associated with chronic diseases and unhealthy aging. This product will offer evidence-based diet and lifestyle recommendations to improve health span.
• Over ten consecutive quarters of sales growth.
  
   

Highlights of the post-Closing combined company are:

• Post-Closing equity valuation of the combined company is expected to be approximately $99 million, with 20/20 having a pre-money equity valuation at approximately $50 million.
• Expected to double Longevity's fiscal year 2025 anticipated revenue from approximately $3-4 million to approximately $7-8 million.
• Expected to realize over $1 million in operational savings and synergies in fiscal year 2025.
• Longevity will offer 20/20 diagnostic tests to its network of physicians to help them design patient-specific bio-aesthetic protocols based on healthy aging.
• Longevity will offer skincare products to 20/20's customer base of thousands of firefighters who are routinely exposed to extreme environments.
• Upon the Closing, Mr. Rajiv Shukla, Chairman and CEO of Longevity, will remain Chairman while Mr. Jonathan Cohen will be appointed CEO of the combined company.